<DOC>
	<DOCNO>NCT02947165</DOCNO>
	<brief_summary>To characterize safety tolerability NIS793 single agent combination PDR001 identify recommend dos future study .</brief_summary>
	<brief_title>Phase I/Ib Study NIS793 Combination With PDR001 Patients With Advanced Malignancies .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>1 . Written informed consent must obtain prior screen procedure . 2 . Patient ( male female ) ≥ 18 year age . 3 . Escalation : Patients advanced/metastatic solid tumor , measurable nonmeasurable disease determine RECIST version 1.1 progress despite standard therapy intolerant standard therapy , standard therapy exists . 4 . Expansion : Patients advanced/metastatic solid tumor , least one measurable lesion determine RECIST version 1.1 , progress despite standard therapy follow last prior therapy intolerant standard therapy fit one follow group : Group 1 : NSCLC ; Group 2 : TNBC ; Group 3 : HCC ; Group 4 : MSSCRC ; Group 5 : pancreatic , prostate ccRCC . 5 . ECOG Performance Status ≤ 2 . 6 . Patients must site disease amenable biopsy , candidate tumor biopsy . Patient must willing undergo new tumor biopsy screening , therapy study . Exceptions may make case case basis document discussion Novartis . 1 . History severe hypersensitivity reaction study treatment ingredient monoclonal antibody component study drug . 2 . Patients active , know suspected autoimmune disease . Note : Patients vitiligo , type I diabetes mellitus , residual hypothyroidism require hormone replacement , psoriasis require systemic treatment , condition expect recur absence external trigger permit enroll . 3 . HIV infection . 4 . Active HBV HCV infection . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>